GlassScriptPhysician profile
Mark D Nathan
NPI 1013947670
$158,244.63
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $23K · 2021: $39K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82,521.08 | 2019-2021 | |
| Lilly USA, LLC | $39,107.53 | 2019-2021 | |
| Astellas Pharma US INC | $19,967.81 | 2019-2020 | |
| Amgen INC. | $6,784.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $6,621.66 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,647.50 | 2019 | |
| Medtronic Vascular, INC. | $819.14 | 2019 | |
| Pfizer INC. | $351.40 | 2019 | |
| Heartflow, INC. | $163.12 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $132.30 | 2019 | |
| Biotronik INC. | $39.17 | 2020 | |
| Janssen Pharmaceuticals, INC | $38.92 | 2019 | |
| Merck Sharp & Dohme LLC | $21.85 | 2021 | |
| Terumo Medical Corporation | $14.92 | 2021 | |
| Boston Scientific Corporation | $13.33 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.